Organovo Holdings, Inc. (ONVO)
NASDAQ: ONVO · Real-Time Price · USD
0.350
+0.009 (2.58%)
At close: Nov 20, 2024, 4:00 PM
0.335
-0.015 (-4.29%)
Pre-market: Nov 21, 2024, 4:10 AM EST
Organovo Holdings Employees
As of March 31, 2024, Organovo Holdings had 20 total employees, including 12 full-time and 8 part-time employees. The number of employees decreased by 4 or -16.67% compared to the previous year.
Employees
20
Change (1Y)
-4
Growth (1Y)
-16.67%
Revenue / Employee
$5,150
Profits / Employee
-$627,100
Market Cap
5.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Mainz Biomed | 71 |
| Kindly MD | 65 |
| Biomerica | 64 |
| Sharps Technology | 57 |
| Applied DNA Sciences | 55 |
| Aptevo Therapeutics | 40 |
| Aethlon Medical | 14 |
| Mangoceuticals | 3 |
ONVO News
- 22 hours ago - Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - GlobeNewsWire
- 7 days ago - Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - GlobeNewsWire
- 4 months ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July - Benzinga
- 4 months ago - Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis - GlobeNewsWire
- 6 months ago - Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease - GlobeNewsWire
- 6 months ago - Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) - GlobeNewsWire
- 7 months ago - Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering - GlobeNewsWire
- 7 months ago - Organovo's fatty liver disease drug meets main goal in mid-stage study - Reuters